Insights into RAS-driven melanoma and its therapeutic implications

Area of Science:

• Oncology
• Genetics
• Immunology

Background:

• NRAS mutations occur in 15-25% of cutaneous melanomas, primarily at codon 61.
• KRAS alterations are less common in cutaneous melanoma but more frequent in brain metastases and mucosal/acral subtypes.

Purpose of the Study:

• To review current and emerging therapeutic strategies for RAS-mutant melanoma.
• To highlight the potential of personalized, biomarker-informed treatment approaches.

Main Methods:

• Literature review of current systemic therapies and investigational approaches for RAS-mutant melanoma.
• Analysis of emerging targeted therapies, including MEK inhibitors, RAF inhibitors, and novel RAS-specific inhibitors.
• Exploration of immunotherapy strategies, including neoepitope-based vaccines.

Main Results:

• Current systemic therapy relies on anti-PD-1 immune checkpoint inhibition, with MEK inhibitors showing modest benefit due to resistance.
• Combination strategies (e.g., MEK with RAF inhibitors) and investigational agents (e.g., G12C inhibitors, pan-RAS inhibitors, mRNA vaccines) are under development.
• NRAS Q61K-derived neoepitopes demonstrate immunogenicity, supporting mutation-specific immunotherapy.

Conclusions:

• Emerging therapies are poised to revolutionize RAS-driven melanoma management.
• Personalized, biomarker-informed strategies are crucial for optimizing patient outcomes in RAS-mutant melanoma.